[{"orgOrder":0,"company":"Springs Rejuvenation","sponsor":"Springs Rejuvenation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Merger","leadProduct":"Stem Cell Therapy","moa":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Springs Rejuvenation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Springs Rejuvenation \/ Springs Rejuvenation","highestDevelopmentStatusID":"1","companyTruncated":"Springs Rejuvenation \/ Springs Rejuvenation"}]

Find Clinical Drug Pipeline Developments & Deals by Springs Rejuvenation

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The combined entity will focus on stem cell therapy, facial rejuvenation, hair rejuvenation, non-surgical hair restoration, protein rich plasma (PRP) injections, and anti-aging treatments.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 20, 2021

                          Lead Product(s) : Stem Cell Therapy

                          Therapeutic Area : Dermatology

                          Highest Development Status : Undisclosed

                          Recipient : Avra

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank